Unlocking the Antiviral Arsenal: Multiparametric Optimization of Small-Molecule Inhibitors against RSV and hCoV-229E

13 February 2024, Version 1


Acute respiratory diseases in humans can be caused by various viral pathogens such as respiratory syncytial virus (RSV), human coronavirus 229E (hCoV-229E), and severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2). To prevent severe cases by an early treatment, one effective strategy is to inhibit viral infection at the entry stage of the replication cycle. However, there is a lack of efficient, FDA-approved small molecule drugs targeting these pathogens. Previously, we identified two dual RSV/hCoV-229E small molecule inhibitors with activity in the single-digit micromolar range. In this study, we focused on optimizing the more promising starting point using a multiparametric hit optimization approach. Here, we present the results, including valuable insights into the structure activity relationship (SAR), and report the discovery of a submicromolar RSV entry inhibitor and a highly potent compound against hCoV-229E.


respiratory syncytial virus
small-molecule inhibitors

Supplementary materials

Supplementary Material
Purity analysis based on LC-MS data of commercial and synthesized, tested compounds, 1H and 13C NMR spectra, dose response curves of all compounds showing activity in single-point measurements, data of ADME studies (kinetic solubility and metabolic stability).


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.